BIBLIOGRAPHY
There are over 185,000 scientific articles published and registered on Immunotherapy and Cancer in the U.S. National Library of Medicine.1. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy. understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807-821. doi. 10.1038/s41423-020-0488-6. Epub 2020 Jul 1. PMID. 32612154; PMCID. PMC7395159.
2. Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and Prevention of Pancreatic Cancer. Trends Cancer. 2018 Jun;4(6):418-428. doi. 10.1016/j.trecan.2018.04.001. Epub 2018 Apr 30. PMID. 29860986; PMCID. PMC6028935.
3. Abbott M, Ustoyev Y. Cancer and the Immune System. The History and Backgroundof Immunotherapy. Semin Oncol Nurs. 2019 Oct;35(5):150923. doi. 1016/j.soncn.2019.08.002. Epub 2019 Sep 13. PMID. 31526550.
4. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167-89. doi. 10.1080/10408360902937809. PMID. 19650714.
5. Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020 Mar;70(2):86-104. doi. 10.3322/caac.21596. Epub 2020 Jan 16. PMID. 31944278.
6. Cha JH, Chan LC, Song MS, Hung MC. New Approaches on Cancer Immunotherapy. Cold Spring Harb Perspect Med. 2020 Aug 3;10(8):a036863. doi. 10.1101/cshperspect.a036863. PMID. 31615865; PMCID. PMC7156317.
7. Szeto GL, Finley SD. Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019 Jul;5(7):400-410. doi. 10.1016/j.trecan.2019.05.010. PMID. 31311655; PMCID. PMC7467854.
8. Igarashi Y, Sasada T. Cancer Vaccines. Toward the Next Breakthrough in Cancer Immuno therapy. J Immunol Res. 2020 Nov 17;2020:5825401. doi:10.1155/2020/5825401. PMID. 33282961; PMCID. PMC7685825.
9. Li K, Zhang A, Li X, Zhang H, Zhao L. Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188615. doi. 10.1016/j.bbcan.2021. 188615. Epub 2021 Aug 14. PMID. 34403771.
10. Bergman PJ. Cancer Immunotherapy. Vet Clin North Am Small Anim Pract. 2024 May;54(3). 441-468. doi. 10.1016/j.cvsm.2023.12.002. Epub 2023 Dec 28. PMID:38158304.
11. O'Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019 Mar;16(3):151-167. doi:10.1038/s41571-018-0142-8. PMID. 30523282.
12. Rui R, Zhou L, He S. Cancer immunotherapies. advances and bottlenecks. Front Immunol. 2023 Aug 24;14:1212476. doi. 10.3389/fimmu.2023.1212476. PMID. 37691932; PMCID. PMC10484345.
13. Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR. Harnessing the immune systemagainst cancer. current immunotherapy approaches and therapeutic targets. MolBiol Rep. 2021 Dec;48(12):8075-8095. doi. 10.1007/s11033-021-06752-9. Epub 2021>Oct 20. PMID. 34671902; PMCID. PMC8605995.
14. Monk BJ, Enomoto T, Kast WM, McCormack M, Tan DSP, Wu X, González-Martín A.Integration of immunotherapy into treatment of cervical cancer. Recent data andongoing trials. Cancer Treat Rev. 2022 May;106:102385. doi:10.1016/j.ctrv.2022.102385. Epub 2022 Mar 31. PMID. 35413489; PMCID:PMC10697630.
15. Velcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches
in Cancer. Am Soc Clin Oncol Educ Book. 2016;35:298-308. doi:10.1200/EDBK_156572. PMID. 27249709.
16. Hines JB, Kacew AJ, Sweis RF. The Development of STING Agonists and EmergingResults as a Cancer Immunotherapy. Curr Oncol Rep. 2023 Mar;25(3):189-199. doi:10.1007/s11912-023-01361-0. Epub 2023 Jan 27. PMID. 36705879; PMCID:PMC10994474.
17. Li A, Yi M, Qin S, Song Y, Chu Q, Wu K. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019 Apr 1;12(1):35. doi. 10.1186/s13045-019-0721-x. PMID. 30935414; PMCID. PMC6444510.
18. Wang X, Fan S, Pan H, Chen W, Wang H. Cancer immunotherapy for metastasis. past, present and future. Brief Funct Genomics. 2019 Mar 22;18(2):140-146. doi. 10.1093/bfgp/ely022. PMID. 29992233.
19. Yu WD, Sun G, Li J, Xu J, Wang X. Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy. Cancer Lett. 2019 Jun 28;452:66-70. doi. 10.1016/j.canlet.2019.02.048. Epub 2019 Mar 19. PMID. 30902563.
20. Tian Y, Xie D, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduct Target Ther. 2022 Apr 6;7(1):117. doi:10.1038/s41392-022-00951-x. PMID. 35387984; PMCID. PMC8987060.
21. Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023 Sep;20(9):604-623. doi. 10.1038/s41571-023-00789-4. Epub 2023 Jun 16. PMID. 37328642.
22. Chen Y, Yu D, Qian H, Shi Y, Tao Z. CD8+ T cell-based cancer immunotherapy. J Transl Med. 2024 Apr 29;22(1):394. doi:10.1186/s12967-024-05134-6. PMID. 38685033; PMCID. PMC11057112.
23. Tang J, Zhu Q, Li Z, Yang J, Lai Y. Natural Killer Cell-targetedImmunotherapy for Cancer. Curr Stem Cell Res Ther. 2022;17(6):513-526. doi:10.2174/1574888X17666220107101722. PMID. 34994316.
24. Demaria O, Gauthier L, Debroas G, Vivier E. Natural killer cell engagers in cancer immunotherapy. Next generation of immuno-oncology treatments. Eur J Immunol. 2021 Aug;51(8):1934-1942. doi. 10.1002/eji.202048953. Epub 2021 Jun 18.PMID. 34145579.
25. Castellanos EH, Horn L. Immunotherapy in Lung Cancer. Cancer Treat Res.2016;170:203-23. doi. 10.1007/978-3-319-40389-2_10. PMID. 27535396; PMCID:PMC10225069.
26. Kassab J, Saba L, Gebrael G, Kais S, Kassab R, Kourie HR. Update onimmunotherapy in the management of gallbladder cancer. Immunotherapy. 2023Jan;15(1):35-42. doi. 10.2217/imt-2022-0191. Epub 2023 Jan 9. PMID. 36617963.
27. Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma. Curr Oncol. 2020 Feb;27(Suppl 1):17-23. doi. 10.3747/co.27.5407. Epub 2020 Feb 1. PMID. 32174754;PMCID. PMC7050043.
28. Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances in personalized cancer immune therapy. Breast Cancer. 2017 Jan;24(1):16-24. doi:10.1007/s12282-016-0688-1. Epub 2016 Mar 21. PMID. 27000871.
29. Bateman AC. Molecules in cancer immunotherapy. benefits and side effects. J Clin Pathol. 2019 Jan;72(1):20-24. doi. 10.1136/jclinpath-2018-205370. Epub 2018 Oct 1. PMID. 30275101.
30. Chen C, Liu X, Chang CY, Wang HY, Wang RF. The Interplay between T Cells and Cancer. The Basis of Immunotherapy. Genes (Basel). 2023 Apr 28;14(5):1008. doi:10.3390/genes14051008. PMID. 37239368; PMCID. PMC10218245.
31. Jindal V. Immunotherapy. a glimmer of hope for metastatic prostate cancer. Chin Clin Oncol. 2018 Dec;7(6):61. doi. 10.21037/cco.2018.02.01. Epub 2018 Mar 12. PMID. 29860848.
32. Mullane SA, Bellmunt J. Cancer immunotherapy. new applications in urologic oncology. Curr Opin Urol. 2016 Nov;26(6):556-63. doi:10.1097/MOU.0000000000000337. PMID. 27584023.
33. Terrén I, Orrantia A, Vitallé J, Astarloa-Pando G, Zenarruzabeitia O, Borrego F. Modulating NK cell metabolism for cancer immunotherapy. Semin Hematol. 2020 Oct;57(4):213-224. doi. 10.1053/j.seminhematol.2020.10.003. Epub 2020 Oct 26. PMID. 33256914.
34. Bergman PJ. Cancer Immunotherapies. Vet Clin North Am Small Anim Pract. 2019Sep;49(5):881-902. doi. 10.1016/j.cvsm.2019.04.010. Epub 2019 Jun 8. PMID. 31186125.
35. Kamrani A, Nasiri H, Hassanzadeh A, Ahmadian Heris J, Mohammadinasab R, Sadeghvand S, Sadeghi M, Valedkarimi Z, Hosseinzadeh R, Shomali N, Akbari M. New immunotherapy approaches for colorectal cancer. focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Commun Signal. 2024 Jan 19;22(1):56. doi:10.1186/s12964-023-01430-8. PMID. 38243252; PMCID. PMC10799490.
36. Gedye C, van der Westhuizen A, John T. Checkpoint immunotherapy for cancer. superior survival, unaccustomed toxicities. Intern Med J. 2015 Jul;45(7):696-701. doi. 0.1111/imj.12653. PMID. 25444021.
37. Nersesian S, Carter EB, Lee SN, Westhaver LP, Boudreau JE. Killer instincts:natural killer cells as multifactorial cancer immunotherapy. Front Immunol. 2023 Nov 28;14:1269614. doi. 10.3389/fimmu.2023.1269614. PMID. 38090565; PMCID:PMC10715270.
38. Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends Cancer. 2024 Aug;10(8):749-769. doi. 10.1016/j.trecan.2024.06.003. Epub 2024 Jul 23. PMID. 39048489.
39. Chen X, Jiang L, Liu X. Natural killer cells. the next wave in cancer immunotherapy. Front Immunol. 2022 Jul 27;13:954804. doi:10.3389/fimmu.2022.954804. PMID. 35967421; PMCID. PMC9364606.
40. Wang Y, Shi T, Song X, Liu B, Wei J. Gene fusion neoantigens. Emerging targets for cancer immunotherapy. Cancer Lett. 2021 May 28;506:45-54. doi. 10.1016/j.canlet.2021.02.023. Epub 2021 Mar 4. PMID. 33675984.
41. Lee P, Gujar S. Potentiating prostate cancer immunotherapy with oncolytic viruses. Nat Rev Urol. 2018 Apr;15(4):235-250. doi. 10.1038/nrurol.2018.10. Epub2018 Feb 13. PMID. 29434366.
42. Kiyotani K, Chan HT, Nakamura Y. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. Cancer Sci. 2018 Mar;109(3):542-549.doi. 10.1111/cas.13498. Epub 2018 Feb 14. PMID. 29288513; PMCID. PMC5834780.
43. Wei X, Wang J, Liang M, Song M. Development of functional nanomedicines fortumor associated macrophages-focused cancer immunotherapy. Theranostics. 2022Nov 14;12(18):7821-7852. doi. 10.7150/thno.78572. PMID. 36451865; PMCID:PMC9706587.
44. Bethune MT, Joglekar AV. Personalized T cell-mediated cancer immunotherapy:progress and challenges. Curr Opin Biotechnol. 2017 Dec;48:142-152. doi:10.1016/j.copbio .2017.03. 024. Epub 2017 May 8. PMID. 28494274.
45. Pan C, Liu H, Robins E, Song W, Liu D, Li Z, Zheng L. Next-generation immuno-oncology agents. current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020 Apr 3;13(1):29. doi. 10.1186/s13045-020-00862-w. PMID. 32245497; PMCID. PMC7119170.
46. El-Mayta R, Zhang Z, Hamilton AG, Mitchell MJ. Delivery technologies to engineer natural killer cells for cancer immunotherapy. Cancer Gene Ther. 2021 Sep;28(9):947-959. doi. 10.1038/s41417-021-00336-2. Epub 2021 Apr 22. PMID. 33888870.
47. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH. Autoimmunity associated with immunotherapy of cancer. Blood. 2011 Jul 21;118(3):499-509. doi. 10.1182/blood-2011-01-325266. Epub 2011 Apr 29.
48. Wellhausen N, Agarwal S, Rommel PC, Gill SI, June CH. Better living through chemistry. CRISPR/Cas engineered T cells for cancer immunotherapy. Curr Opin Immunol. 2022 Feb;74:76-84. doi. 10.1016/j.coi.2021.10.008. Epub 2021 Nov 16. PMID. 34798542; PMCID. PMC9337770.
49. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy. a paradigm shift. J Natl Cancer Inst. 2013 Feb 20;105(4):256-65. doi. 10.1093/jnci/djs629. Epub 2013 Jan 4. PMID. 23291374; PMCID. PMC3576324.
50. American Society of Clinical Oncology (ASCO). ASCO Annual Meeting 2019. Immuno therapy for lung cancer, gastrointestinal cancers and targeted therapy for breast cancer. Accessed at https://www.cancer.net/blog/2019-06/asco-annual-meeting-2019-immuno therapy-lung-cancer-gastrointestinal-cancers-and-targeted-therapy on December 19, 2019.
51. American Society of Clinical Oncology (ASCO). Understanding immunotherapy. Accessed at https://www.cancer.net/navigating-cancer-care/how-cancer- Treated / immunotherapy-and-vaccines/understanding-immunotherapy on December 19, 2019.
52. Bayer VR, Davis ME, Gordan RA, et al. Immunotherapy. In Olsen MM, LeFebvre KB, Brassil KJ, eds. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA. Oncology Nursing Society; 2019:149-189.
53 . Bousquet E, Zarbo A, Tournier E, et al. Development of papulopustular rosacea during nivolumab therapy for metastatic cancer. Act Derm Venereol. 2017; 97(4):539—540.
54. Hong D, Sloane DE. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue disease. Ann Allergy Asthma Immunol. 2019; 123(1):35-41.Kaunitz GJ, Loss M, Rizvi et al. Cutaneous eruptions in patients receiving immune checkpoint blockade. Clinicopathologic analysis of the nonlichenoid histologic pattern. Am J Surg Pathol. 2017; 41(10):1381-1389.
55. National Cancer Institute (NCI). Immunotherapy to treat cancer. Accessed at www.cancer.gov /about-cancer/treatment/types/immunotherapy on December 19,2019
56. American Society of Clinical Oncology (ASCO). ASCO Annual Meeting 2019:Immunotherapy for lung cancer, gastrointestinal cancers and targeted therapy for breastcancer. Accessed at https://www.cancer.net/blog/2019-06/asco-annual-meeting-2019-immunotherapy-lung-cancer-gastrointestinal-cancers-and-targeted-therapy onDecember 19, 2019.
57. American Society of Clinical Oncology (ASCO). Understanding immunotherapy. Accessed at https://www.cancer.net/navigating-cancer-care/how-cancer-treated/immunotherapy-and-vaccines/understanding-immunotherapy on December 19,2019.
58. Bayer VR, Davis ME, Gordan RA, et al. Immunotherapy. In Olsen MM, LeFebvre KB, Brassil KJ, eds. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA. Oncology Nursing Society; 2019:149-189.National Cancer Institute (NCI). (NCI). CAR T cells. Engineering patients’ immune cells to treat their cancers. Accessed at https://www.cancer.gov/about- cancer/treatment/research/car-t-cells on December 19, 2019.Porter DL, Maloney DG. Cytokine release syndrome (CRS). UpToDate. 2021. Accessed at https://www.uptodate.com/contents/cytokine-release-syndrome-crs on April 01, 2021.National Cancer Institute website. CAR T cells. engineering patients' immune cells to treat their cancers. www.cancer.gov/about-cancer/treatment/research/car-t-cells. Updated March 10, 2022. Accessed June 13, 2024.National Cancer Institute website. Immunotherapy to treat cancer. www.cancer.gov/about-cancer/treatment/types/immunotherapy. Updated September 24, 2019. Accessed June 13, 2024.Tseng D, Schultz L, Pardoll D, Mackall C. Cancer immunology. In. Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff's Clinical Oncology. 6th ed. Philadelphia, PA. Elsevier; 2020:chap 6.